We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.19%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$522M
AUM Growth
-$148M
Cap. Flow
-$183M
Cap. Flow %
-35.1%
Top 10 Hldgs %
68.85%
Holding
172
New
42
Increased
30
Reduced
27
Closed
64

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.7M
2
AZN icon
AstraZeneca
AZN
+$11.5M
3
XWEL icon
XWELL
XWEL
+$3.81M
4
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$3.63M
5
CVM icon
CEL-SCI Corp
CVM
+$2.66M

Top Sells

Rank Stock Value
1
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$4.87M
2
IMMU
Immunomedics Inc
IMMU
+$4.25M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.12M
4
SPI
SPI Energy Co., Ltd. Ordinary Shares
SPI
+$3.57M
5
RMTI icon
Rockwell Medical
RMTI
+$3.04M

Sector Composition

Rank Sector Weight
1 Healthcare 17.64%
2 Industrials 0.71%
3 Technology 0.22%
4 Consumer Discretionary 0.14%
5 Consumer Staples 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
126
Kyntra Bio
KYNB
$27.4M
– –
-1,186
Closed -$1.22M
KYNB
127
PUT
Kyntra Bio
KYNB
$27.4M
– –
-57
Closed -$5.83M
HEPA
128
DELISTED
Hepion Pharmaceuticals
HEPA
– –
-57
Closed -$148K
IBB icon
129
iShares Biotechnology ETF
IBB
$9.45B
– –
-11,372
Closed -$1.54M
LMFA
130
DELISTED
LM Funding America
LMFA
– –
-196
Closed -$97K
LPCN icon
131
CALL
Lipocine
LPCN
$17.1M
– –
-55
Closed -$133K
LPCN icon
132
Lipocine
LPCN
$17.1M
– –
-26,086
Closed -$625K
LPCN icon
133
PUT
Lipocine
LPCN
$17.1M
– –
-9
Closed -$21K
LSTA icon
134
Lisata Therapeutics
LSTA
$9.93M
– –
-6,400
Closed -$152K
OLB icon
135
OLB
OLB
$4.03M
– –
-31,101
Closed -$1.17M
PALI icon
136
Palisade Bio
PALI
$341M
– –
-87
Closed -$229K
PDSB icon
137
PDS Biotechnology
PDSB
$37.4M
– –
-419,836
Closed -$978K
PFE icon
138
CALL
Pfizer
PFE
$143B
– –
-1,915
Closed -$6.67M
PLUR icon
139
Pluri
PLUR
$17M
– –
-7,466
Closed -$629K
PLUR icon
140
PUT
Pluri
PLUR
$17M
– –
-748
Closed -$6.3M
SCPH
141
DELISTED
scPharmaceuticals
SCPH
– –
-42,407
Closed -$316K
SHIP icon
142
Seanergy Maritime Holdings
SHIP
$349M
– –
-534,928
Closed -$2.44M
SPY icon
143
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$771B
– –
-867
Closed -$29M
SRPT icon
144
CALL
Sarepta Therapeutics
SRPT
$1.64B
– –
-44
Closed -$618K
SRPT icon
145
PUT
Sarepta Therapeutics
SRPT
$1.64B
– –
-76
Closed -$1.07M
TSLA icon
146
CALL
Tesla
TSLA
$1.18T
– –
-2,550
Closed -$36.5M
TSLA icon
147
PUT
Tesla
TSLA
$1.18T
– –
-1,305
Closed -$21.4M
TTNP
148
DELISTED
Titan Pharmaceuticals
TTNP
– –
-8,095
Closed -$803K
BSIN
149
Big Sky Industrial
BSIN
$58.6M
– –
-66,504
Closed -$333K
VXX icon
150
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
$169M
– –
-1,563
Closed -$2.49M
3 4 5
6
7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sabby Management held 172 positions worth $522M, down 22% from $670M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management withdrew a net $183M in Q4 2020, closing 64 positions and reducing 27 holdings. Its most notable exit was Sorrento Therapeutics, Inc., an estimated $4.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 12% a quarter earlier, followed by Industrials and Technology.

Against the trend, Sabby Management opened a new position in REVIVA PHARMA HLDGS INC worth $3.13M.

  • Sabby Management's largest Q4 2020 buy was REVIVA PHARMA HLDGS INC: 17,915 shares worth $3.13M.
  • Sabby Management added most to Biogen in Q4 2020, an estimated $18.7M increase.
  • Sabby Management's biggest Q4 2020 reduction was Rockwell Medical, cutting an estimated $3.04M.
  • Sabby Management fully exited Sorrento Therapeutics, Inc. in Q4 2020, selling an estimated $4.87M.
  • Sabby Management's ten largest holdings make up 69% of its $522M portfolio in Q4 2020.
  • Sabby Management opened 42 new positions and closed 64 in Q4 2020.
  • Sabby Management's portfolio value fell 22% quarter-over-quarter to $522M.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.